title: Relations between plasma von Willebrand factor or endothelin-1 and restenosis following carotid artery stenting.
abstract: OBJECTIVE
  This study was designed to investigate the relation between plasma von Willebrand factor (VWF) or endothelin-1 (ET-1) and post-carotid artery stenting (CAS) restenosis.
  
  
  METHODS
  Plasma levels of VWF and ET-1 were measured in 61 patients (36 males, mean age 64.4 ± 6.8 years) before and after CAS. The mean follow-up time was 13.8 ± 1.7 months (range, 6-63). In-stent restenosis was defined as a >10% narrowing of the vascular lumen with or without ischemic symptoms following CAS.
  
  
  RESULTS
  In-stent restenosis was identified in 14 (23%) patients, including 3 with >50% restenosis. In the restenosis group, mean VWF and ET-1 levels at 2 weeks, 1 and 6 months after CAS were higher than the baseline levels (p < 0.05 or p < 0.01). Mean levels of VWF and ET-1 in the restenosis group were higher than in the non-restenosis group within 6 months after CAS (p < 0.05 or p < 0.01).
  
  
  CONCLUSIONS
  Persistent elevation in plasma VWF and ET-1 within the first 6 months of CAS was found in patients with in-stent restenosis.
authors.affiliation: Department of Neurology, the Third People's Hospital of Liaocheng, Liaocheng, PR China.
authors.forename: Hua
authors.initials: H
authors.lastname: Yang
authors.forename: Jian-Xin
authors.initials: JX
authors.lastname: Xu
authors.forename: Xiang-Zhi
authors.initials: XZ
authors.lastname: Kong
authors.forename: Zeng-Guang
authors.initials: ZG
authors.lastname: Ren
authors.forename: Zhang-Yong
authors.initials: ZY
authors.lastname: Xia
authors.forename: Huai-Qian
authors.initials: HQ
authors.lastname: Qu
authors.forename: Le-Xin
authors.initials: LX
authors.lastname: Wang
mesh_terms: D000368:Aged; D000704:Analysis of Variance; D054316:Biomarkers, Pharmacological; D023903:Coronary Restenosis / Q000175:diagnosis* / Q000188:drug therapy / Q000473:pathology; D003331:Coronary Vessels / Q000473:pathology*; D054855:Drug-Eluting Stents; D019332:Endothelin-1 / Q000097:blood*; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D011379:Prognosis; D011446:Prospective Studies; D018570:Risk Assessment / Q000379:methods; D020521:Stroke; D014841:von Willebrand Factor
chemical_list: D054316:Biomarkers, Pharmacological; D019332:Endothelin-1; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D010975:Platelet Aggregation Inhibitors; D014841:von Willebrand Factor